Market Place
Sourcing Support
Medunik USA Expands Medicaid Coverage And Support Services For Pheburane
17 Sep 2024 //
PR NEWSWIRE
Zevra Presents New Data On Arimoclomol And OLPRUVA At SSIEM Symposium
06 Sep 2024 //
GLOBENEWSWIRE
Amylyx Publishes AMX0035 Data On Alzheimer`s Biomarkers
12 Aug 2024 //
BUSINESSWIRE
Zevra Transitions To Orsini As Provider For OLPRUVA® In Urea Cycle Disorders
18 Jun 2024 //
GLOBENEWSWIRE
Amylyx stock slips 6% after phase 2 rare disease data drop
11 Apr 2024 //
FIERCE BIOTECH
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
05 Apr 2024 //
PRESS RELEASE
Amylyx Announces to Remove RELYVRIO®/ALBRIOZA™ from the Market
04 Apr 2024 //
BUSINESSWIRE
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
09 Mar 2024 //
PRESS RELEASE
Pheburane is now on the Medicaid Preferred Drug List in 10 states
23 Jan 2024 //
PR NEWSWIRE
RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND
27 Nov 2023 //
BUSINESSWIRE
Pheburane coverage to reach ~80% of commercially insured US patients
26 Oct 2023 //
GLOBENEWSWIRE
Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again
14 Oct 2023 //
FIERCE PHARMA
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual NEALS Meeting
02 Oct 2023 //
BUSINESSWIRE
Pheburane coverage expands to the benefit of Americans with certain UCDs
09 Aug 2023 //
GLOBENEWSWIRE
Amylyx to appeal EMA panel recommendation against ALS drug
24 Jun 2023 //
ENDPTS
Amylyx`s Relyvrio pulls in $71M in revenue
12 May 2023 //
ENDPTS
Relief Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch
01 May 2023 //
PHARMIWEB
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
15 Mar 2023 //
ACCESSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
23 Dec 2022 //
PIPELINEREVIEW
US FDA gives final approval to Glenmark Pharma’s Sodium Phenylbutyrate tablets
03 Nov 2022 //
EXPRESSPHARMA
Glenmark`s Generic Sodium Phenylbutyrate Receives Approval in the U.S.
01 Nov 2022 //
FDA
Amylyx`s ALS drug finally approved by FDA
30 Sep 2022 //
FIERCEPHARMA
Amylyx Announces Donated CENTAUR Trial Data Available to Advance Science in ALS
14 Sep 2022 //
PRESS RELEASE
Amylyx Announces Donated CENTAUR Trial Data Available to Help Advance Science
14 Sep 2022 //
BUSINESSWIRE
Amylyx Announces Publication of Data Showing Potential Effect of AMX0035
12 Sep 2022 //
BUSINESSWIRE
Amylyx Pharma Stock Trading Halted Today
07 Sep 2022 //
BUSINESSWIRE
Amylyx Announces FDA Advisory Committee Supports Approval of AMX0035
07 Sep 2022 //
BUSINESSWIRE
Amylyx Announces Posting of Briefing Documents for FDA Meeting on AMX0035
02 Sep 2022 //
BUSINESSWIRE
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Amylyx Announces FDA Will Reconvene to Review New Drug Application
03 Aug 2022 //
BUSINESSWIRE
Acer Therapeutics Resubmits NDA For ACER-001 in Urea Cycle Disorders
19 Jul 2022 //
NASDAQ
Relief Tx Announces that its Collaboration Partner has Resubmitted ACER-001 NDA
18 Jul 2022 //
BIOSPACE
Amylyx Pharma Announces Health Canada Approval of ALBRIOZA for ALS
13 Jun 2022 //
AMYLYX
Amylyx Pharmaceuticals Stock Trading Halted Today
30 Mar 2022 //
BUSINESSWIRE
Amylyx Pharma Announces Posting of Briefing Documents for FDA Advisory Committee
28 Mar 2022 //
BUSINESSWIRE
Amylyx Announces EMA Validation of MAA for AMX0035 in ALS
25 Feb 2022 //
BUSINESSWIRE
CNDR, Amylyx Partner on Real-World Evidence Generation for Novel Therapy in ALS
03 Feb 2022 //
BUSINESSWIRE
Acer was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use
01 Feb 2022 //
BIOSPACE
Amylyx Pharmaceuticals Submits MAA for AMX0035 for the Treatment of ALS
04 Jan 2022 //
BUSINESSWIRE
Acer Therapeutics and Relief Announce Issuance of U.S. Patent ACER-001
26 Oct 2021 //
GLOBENEWSWIRE
Acer & Relief Announce FDA Acceptance for Filing of NDA for ACER-001
06 Oct 2021 //
GLOBENEWSWIRE
Enforcement Report - Week of October 6, 2021
06 Oct 2021 //
FDA
Amylyx Pharmaceuticals to Submit NDA for AMX0035 for ALS
15 Sep 2021 //
BUSINESSWIRE
Enforcement Report - Week of September 1, 2021
01 Sep 2021 //
FDA
Amylyx Pharmaceuticals Announces Phase 2 Study of AMX0035
04 Oct 2019 //
BUSINESSWIRE
Acer Therapeutics Restructures Company, Eliminates 29 Employees
08 Jul 2019 //
BIOSPACE
FDA kicks back Acer`s rare disease drug, demands new test—shares in freefall
26 Jun 2019 //
FIERCE BIOTECH
Orion takes repurposed heart drug into phase 3 for ALS
06 Jul 2018 //
FIERCE BIOTECH
Enforcement Report - Week of May 24, 2017
24 May 2017 //
FDA
Sobi & Horizon enter five-year distribution agreement for Ravicti & Ammonaps
07 Dec 2016 //
PR NEWSWIRE
Pii faces EU ban following GMP issues at Maryland facilities
19 Sep 2016 //
IN-PHARMATECHNOLOGIST
EMA’s CHMP Recommends Ban of US CMO’s Medicines
16 Sep 2016 //
RAPS
Horizon to Buy Hyperion for $1.1 Billion, Gain Orphan Drugs
31 Mar 2015 //
BLOOMBERG BUSINESS
